Table 1 Patient characteristics
All | sUA < 6.0 mg/dl | sUA ≥ 6.0 mg/dl | p value | |
|---|---|---|---|---|
Patients, n (%) | 178 | 78 | 100 | |
Male, n (%) | 121 (68%) | 42 (54%) | 79 (79%) | < 0.001 |
Age, years (range) | 65 (15–89) | 66 (17–89) | 64 (15–88) | n.s. |
Baseline systolic BP, mmHg (range) | 130 (85–180) | 129 (85–170) | 130 (96–180) | n.s. |
Baseline diastolic BP, mmHg (range) | 76 (45–110) | 74 (50–110) | 76 (45–106) | n.s. |
Primary diseases of CKD | ||||
Diabetic nephropathy, n (%) | 33 (19%) | 9 (12%) | 24 (24%) | n.s. |
Chronic nephritis, n (%) | 36 (20%) | 19 (24%) | 17 (17%) | n.s. |
Nephrosclerosis, n (%) | 34 (19%) | 14 (18%) | 20 (20%) | n.s. |
Others, n (%) | 75 (42%) | 36 (46%) | 39 (39%) | n.s. |
Complications | ||||
Diabetes mellitus, n (%) | 45 (25%) | 17 (22%) | 28 (28%) | n.s. |
Hypertension, n (%) | 137 (77%) | 56 (72%) | 81 (81%) | n.s. |
Abnormal cholesterol levels, n (%) | 94 (53%) | 34 (44%) | 60 (60%) | n.s. |
Coronary artery disease, n (%) | 12 (7%) | 4 (5%) | 8 (8%) | n.s. |
Estimated GFR at baseline, ml/min/1.73 m2 | 27.0 (7.3–101.7) | 27.7 (7.3–78.9) | 26.0 (9–101.7) | n.s. |
Urine protein levels at baseline, g/gCre | 0.67 (0.00–17.7) | 0.45 (0.00–7.2) | 0.78 (0.00–17.7) | n.s. |
Serum uric acid at baseline, mg/dl | 8.3 (3.9–12.6) | 8.3 (3.9–10.7) | 8.7 (5.2–12.6) | 0.042 |
CKD stage | ||||
G1–2, n (%) | 13 (7%) | 6 (8%) | 7 (7%) | n.s. |
G3, n (%) | 62 (35%) | 29 (37%) | 33 (33%) | n.s. |
G4–5, n (%) | 103 (58%) | 43 (55%) | 60 (60%) | n.s. |
Antihyperuricemics before febuxostat | ||||
None, n (%) | 118 (66%) | 58 (74%) | 60 (60%) | n.s. |
Allopurinol, n (%) | 44 (25%) | 14 (18%) | 30 (30%) | n.s |
Benzbromarone, n (%) | 14 (8%) | 6 (8%) | 8 (8%) | n.s. |
Allopurinol and benzbromarone, n (%) | 2 (1%) | 0 (0%) | 2 (2%) | n.s. |
Febuxostat dose after 6 months | ||||
10 mg/day, n (%) | 103 (58%) | 51 (66%) | 52 (52%) | n.s. |
20 mg/day, n (%) | 61 (34%) | 22 (28%) | 40 (39%) | n.s. |
40 mg/day, n (%) | 14 (8%) | 5 (6%) | 9 (9%) | n.s. |